Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.
Azole antifungals are central to therapy and act by inhibiting a cytochrome P450, sterol 14-demethylase and blocking normal sterol synthesis. Our recent identification of a mycobacterial sterol biosynthetic pathway led us to probe the efficacy of a range of these compounds against Mycobacterium smegmatis. Several showed equivalent or greater inhibitory effects to those against Candida albicans, and bactericidal activity was demonstrated for four compounds, clotrimazole, econazole, miconazole and tebuconazole. The major drug used clinically, fluconazole, was ineffective. The results are discussed in the light of the world-wide spread of tuberculosis, including drug-resistant forms and the requirement for new drugs.
Jackson
C J
CJ
Institute of Biological Sciences, University of Wales Aberystwyth, SY23 3DA, Aberystwyth, UK.
Lamb
D C
DC
Kelly
D E
DE
Kelly
S L
SL
D000935:Antifungal Agents / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D003022:Clotrimazole / Q000494:pharmacology; D004464:Econazole / Q000494:pharmacology; D006131:Growth Inhibitors / Q000494:pharmacology; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D020102:Mycobacterium smegmatis / Q000187:drug effects* / Q000235:genetics; D014230:Triazoles / Q000494:pharmacology
D000935:Antifungal Agents; D000995:Antitubercular Agents; D001393:Azoles; D006131:Growth Inhibitors; D014230:Triazoles; C087114:tebuconazole; D004464:Econazole; D008825:Miconazole; D003022:Clotrimazole